Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$56.15 USD

56.15
4,232,319

+0.70 (1.26%)

Updated Nov 5, 2024 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings

by Zacks Equity Research

Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Ekta Bagri headshot

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

by Ekta Bagri

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49.57, representing a -1.08% change from its previous close.

Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress

by Zacks Equity Research

Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $50 in the latest trading session, marking a -0.62% move from the prior day.

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

by Zacks Equity Research

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Andrew Rocco headshot

Bullish Continuation in '24? 3 Market Areas to Watch

by Andrew Rocco

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Prothena's (PRTA) Update on Pipeline Progress Disappoints

by Zacks Equity Research

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

by Zacks Equity Research

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.

Sweta Killa headshot

Biotech ETFs Stage Solid Comeback at the Start of 2024

by Sweta Killa

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

by Zacks Equity Research

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.30, signifying a -0.87% move from its prior day's close.

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

by Zacks Equity Research

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Ekta Bagri headshot

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

by Ekta Bagri

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

by Zacks Equity Research

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

Company News for Dec 27, 2023

by Zacks Equity Research

Companies In The Article Are: INTC,RYZB,BMY,NIO,MANU